3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
22.4.2025 18:00:00 CEST | Business Wire | Press Release
3Degrees, a leading global climate solutions provider and certified B Corporation, is pleased to announce the appointment of Philippe Vedrenne as Chief Executive Officer (CEO), effective May 1, 2025. Vedrenne is moving into the role as 3Degrees’ current CEO and co-founder Steve McDougal steps away from leadership of the company. McDougal informed the Board of Directors last year that he would be retiring as CEO; he will maintain his involvement as a member of the Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422978066/en/
3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
Vedrenne brings over two decades of global energy market experience operating across multiple continents. Most recently, at Engie, he oversaw trading and retail activities in North and South America for electricity and gas. In this position, he led efforts to bring utility-scale renewable energy solutions to the corporate market by combining wind, solar, and battery asset classes.
Vedrenne began his career in Europe at Gaz de France where he played a foundational role in the creation of Gasely, the trading business unit that evolved into Engie Global Markets, where he later became CEO. While running Engie’s natural gas midstream activities in Europe, he renegotiated the company’s long-term supply contracts to align them with markets, contributed to ensure European security of supply, and helped establish natural gas reverse flows to Ukraine in the wake of the Maidan uprisings and 2014 Russian-Ukrainian war. Before moving to the U.S. in 2021, Vedrenne led two significant projects for Engie: the development of renewable power purchase agreement (PPA) activities in Europe, and the net zero carbon project that defines Engie’s decarbonization ambition and trajectory to carbon neutrality by 2045.
“We are thrilled to welcome Philippe Vedrenne as the next CEO of 3Degrees,” said Dan Kalafatas, 3Degrees’ co-founder and Chair of the Board. “Our global search focused on selecting a new leader with the expertise to drive the next chapters of 3Degrees’ growth. Philippe brings a rare combination of global leadership experience, track record of success, service-leader orientation, and passion for bringing innovative decarbonization solutions to the world. The 3Degrees Board also wants to express deep gratitude to Steve McDougal. In his tenure as CEO, Steve spearheaded the company’s transformation from a small, North American-focused renewable energy commodity company into a leading global climate solutions provider advising some of the largest companies in the world.”
“I could not be more excited to assume the CEO role and help accelerate 3Degrees’ growth and our clients’ climate impact,” said Vedrenne. “The entire team is incredibly strong, with deep market and functional expertise. I’m looking forward to helping fuel the company’s continued expansion in both current and new markets, and to using our unique combination of market participation and client-centric focus to innovate new products and solutions. I’m honored to be asked to join such an exemplary organization, enabling me to work on a challenge of great urgency to us all.”
McDougal added, “Co-founding 3Degrees with Dan Kalafatas, and subsequently leading the company as CEO for the last ten years, has been one of the greatest privileges of my life. I am incredibly proud of what the 3Degrees team has built together over nearly two decades. I look forward to supporting the bright future for 3Degrees in my role on its Board of Directors and feel confident Philippe will be an excellent steward of the company as it expands its impact globally for our clients, partners, suppliers, employees, and the climate.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422978066/en/
Contacts
Rachel Fagan
512.791.2083
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Invivoscribe Announces the PrepQuant ™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows15.4.2026 07:05:00 CEST | Press Release
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that integrates nucleic acid extraction, concentration, and quantification with a single automated instrument. This innovative system is designed to standardize sample preparation and simplify pre-analytical workflows to reduce costs and eliminate a primary source of inconsistency in molecular testing. Developed in collaboration with Hitachi High-Tech Corporation, the PrepQuant System combines Invivoscribe’s expertise in developing standardized molecular assays, providing global clinical testing services, along with Hitachi High-Tech’s proven technological and manufacturing capabilities. Hitachi High-Tech has an extensive global installed base of life science and clinical diagnostic instruments. The PrepQuant System is assay agnostic, generating highly concentrated genomic DNA and cell free DNA (c
Invivoscribe Announces the PrepQuant ™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows15.4.2026 07:05:00 CEST | Press Release
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that integrates nucleic acid extraction, concentration, and quantification with a single automated instrument. This innovative system is designed to standardize sample preparation and simplify pre-analytical workflows to reduce costs and eliminate a primary source of inconsistency in molecular testing. Developed in collaboration with Hitachi High-Tech Corporation, the PrepQuant System combines Invivoscribe’s expertise in developing standardized molecular assays, providing global clinical testing services, along with Hitachi High-Tech’s proven technological and manufacturing capabilities. Hitachi High-Tech has an extensive global installed base of life science and clinical diagnostic instruments. The PrepQuant System is assay agnostic, generating highly concentrated genomic DNA and cell free DNA (c
IFF to Release First Quarter 2026 Results on May 5, 202614.4.2026 22:15:00 CEST | Press Release
IFF (NYSE: IFF) today announced that it will release its first quarter 2026 earnings results following the market close on Tuesday, May 5, 2026. The management team will host a live webcast on Wednesday, May 6, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.business
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom